{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:47:43Z","timestamp":1760298463441},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T00:00:00Z","timestamp":1328140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>The pathogenetic role of vascular endothelial growth factor (VEGF) in malignant pericardial effusion and diagnostic value of pericardial VEGF levels to discriminate malignant from benign pericardial effusions are uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis:<\/jats:title><jats:p>We hypothesized that pericardial VEGF levels would be higher in malignant than benign pericardial effusion and that VEGF would be a useful marker for the diagnosis of malignant pericardial effusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Using an enzyme\u2010linked immunosorbent assay, we assessed pericardial and serum VEGF levels in patients with malignant pericardial effusion (n = 19), in patients with nonmalignant pericardial effusion (n = 30), and for control, in patients without pericardial disease (n = 26).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Vascular endothelial growth factor pericardial levels in malignant pericardial effusion (13 593.8 \u00b1 22 410.24 pg\/mL) were significantly higher compared with VEGF in nonmalignant effusion (610.63 \u00b1 1289.08 pg\/mL; <jats:italic>P<\/jats:italic> = 0.001) and pericardial fluid (5.5 \u00b1 15.97 pg\/mL; <jats:italic>P &lt;<\/jats:italic> 0.001). In serum, VEGF was significantly higher in patients with nonmalignant pericardial effusion (188.3 \u00b1 240.35 pg\/mL) compared with patients with malignant pericardial effusion (67.52 \u00b1 125.77 pg\/mL; <jats:italic>P<\/jats:italic> = 0.024) and coronary artery disease patients (29.13 \u00b1 76.26 pg\/mL; <jats:italic>P &lt;<\/jats:italic> 0.001). Pericardial VEGF levels were significantly higher than matched serum levels only in patients with malignant pericardial effusion (<jats:italic>P<\/jats:italic> = 0.023). Pericardial VEGF levels \u22652385 pg\/mL had 75% sensitivity and 90% specificity for the recognition of malignant pericardial effusion in patients with breast or lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Vascular endothelial growth factor levels in pericardial effusion are markedly elevated in patients with malignant pericardial effusion, indicating abundant local release within the pericardial cavity. It is thus possible that VEGF participates in the pathogenesis of malignant pericardial effusion. Measurement of VEGF in pericardial effusion offers potential as a diagnostic tool to discriminate malignant from benign effusions in patients with breast or lung cancer.<\/jats:p><jats:p>The authors have no funding, financial relationships, or conflicts of interest to disclose.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.21967","type":"journal-article","created":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T20:13:18Z","timestamp":1328213598000},"page":"377-381","source":"Crossref","is-referenced-by-count":18,"title":["Vascular Endothelial Growth Factor in Malignant and Benign Pericardial Effusion"],"prefix":"10.1002","volume":"35","author":[{"given":"Konstantinos","family":"Karatolios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Pankuweit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer Georg","family":"Moosdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040370"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90119-1"},{"key":"e_1_2_6_4_2","first-page":"1255","article-title":"Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.","volume":"143","author":"Brown LF","year":"1993","journal-title":"Am J Pathol."},{"key":"e_1_2_6_5_2","first-page":"4727","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.","volume":"53","author":"Brown LF","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00665960"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2007.03.004"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7"},{"key":"e_1_2_6_10_2","first-page":"360","article-title":"Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.","volume":"55","author":"Nagy JA","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_6_11_2","first-page":"2594","article-title":"Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor\/permeability factor neutralizing antibody.","volume":"58","author":"Luo JC","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_12_2","first-page":"573","article-title":"Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice.","volume":"9","author":"Yano S","year":"1997","journal-title":"Oncol Res."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0373-0"},{"key":"e_1_2_6_14_2","first-page":"957","article-title":"Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.","volume":"6","author":"Yano S","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64828-6"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.02.002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2002.3152"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.10.021"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.5.1259"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.02.002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460089701200302"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460080502000107"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.6.2728"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90800-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.5.1213"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90262-N"},{"key":"e_1_2_6_27_2","first-page":"458","article-title":"VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis [article in Polish].","volume":"70","author":"Ziora D","year":"2002","journal-title":"Pneumonol Alergol Pol."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i11.2596"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2004.apm1120904.x"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.21967","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.21967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:41:34Z","timestamp":1700563294000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.21967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/clc.21967"],"URL":"https:\/\/doi.org\/10.1002\/clc.21967","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,2]]}}}